See more : Enterprise Development Holdings Limited (1808.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Mirum Pharmaceuticals, Inc. (MIRM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mirum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nichiwa Sangyo Co., Ltd. (2055.T) Income Statement Analysis – Financial Results
- Hatsun Agro Product Limited (HATSUN.NS) Income Statement Analysis – Financial Results
- Hanil Cement Co., Ltd. (300720.KS) Income Statement Analysis – Financial Results
- Chih Lien Industrial Co., Ltd. (2024.TW) Income Statement Analysis – Financial Results
- Hear AtLast Holdings, Inc. (HRAL) Income Statement Analysis – Financial Results
Mirum Pharmaceuticals, Inc. (MIRM)
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 186.37M | 77.06M | 19.14M | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 47.04M | 12.37M | 1.90M | 623.00K | 324.00K | 0.00 |
Gross Profit | 139.34M | 64.69M | 17.24M | -623.00K | -324.00K | 0.00 |
Gross Profit Ratio | 74.76% | 83.94% | 90.06% | 0.00% | 0.00% | 0.00% |
Research & Development | 102.61M | 106.84M | 131.43M | 81.61M | 42.99M | 2.33M |
General & Administrative | 139.58M | 16.96M | 59.22M | 22.69M | 11.75M | 877.50K |
Selling & Marketing | 6.30M | 72.11M | 9.20M | 0.00 | 0.00 | -292.50K |
SG&A | 145.88M | 89.07M | 59.22M | 22.69M | 11.75M | 585.00K |
Other Expenses | 0.00 | 365.00K | 107.42M | -192.00K | -21.00K | 0.00 |
Operating Expenses | 248.49M | 195.91M | 190.65M | 104.30M | 54.74M | 2.92M |
Cost & Expenses | 295.53M | 208.28M | 192.55M | 104.30M | 54.74M | 2.92M |
Interest Income | 13.74M | 3.86M | 366.00K | 1.56M | 2.23M | 87.00K |
Interest Expense | 15.11M | 15.98M | 17.59M | 335.00K | 0.00 | 0.00 |
Depreciation & Amortization | 10.83M | 3.68M | 975.00K | 623.00K | 324.00K | 4.37M |
EBITDA | -136.49M | -122.41M | -65.39M | -102.31M | -52.21M | -17.33M |
EBITDA Ratio | -73.23% | -164.80% | -337.83% | 0.00% | 0.00% | 0.00% |
Operating Income | -109.15M | -131.22M | -173.41M | -104.30M | -54.74M | -2.92M |
Operating Income Ratio | -58.57% | -170.28% | -906.12% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -53.27M | -10.85M | 89.46M | 1.03M | 2.21M | -14.43M |
Income Before Tax | -162.42M | -142.07M | -83.95M | -103.26M | -52.53M | -17.35M |
Income Before Tax Ratio | -87.15% | -184.36% | -438.66% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 991.00K | -6.41M | 37.00K | 6.00K | 21.00K | -4.37M |
Net Income | -163.42M | -135.67M | -83.99M | -103.27M | -52.55M | -17.35M |
Net Income Ratio | -87.68% | -176.05% | -438.85% | 0.00% | 0.00% | 0.00% |
EPS | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
EPS Diluted | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
Weighted Avg Shares Out | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
Weighted Avg Shares Out (Dil) | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength?
Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023
Source: https://incomestatements.info
Category: Stock Reports